• info@icbcongress.com
• English
• Persian

• Login

Create Free Account

INTERNATIONAL CONGRESS OF

CancerGenetics

• Evaluation of Common Polymorphisms in Brain Cancer and Assessment of Adverse Effects of Anticancer Drugs

• Majid Mesgartehrani,^1,* Mahtab Panahi,² Mohammad Mehdi Eslami,³ Reza Mirlohi,⁴
  2. Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences.
  
  
  
• Introduction: Cancer, characterized by uncontrolled cell growth and spread, ranks as the second leading cause of death globally, with brain cancer representing a particularly aggressive form affecting both adults and children. Brain tumors, classified as benign or malignant, constitute a significant portion of central nervous system (CNS) malignancies, with gliomas accounting for the majority. Global incidence rates of brain and CNS cancers are rising, with notable geographic and sex-specific variations observed, including a marked increase in Iran surpassing regional and global trends. Risk factors for brain cancer include genetic predispositions, ionizing radiation, and immune-related conditions, though many cases remain idiopathic. Various brain cancer cell lines are used for research, with differing grades and tumor origins. Advances in next-generation sequencing (NGS) technologies have revolutionized genetic analysis, enabling high-throughput, cost-effective sequencing critical for cancer research. Despite challenges in data management and interpretation due to the massive output of NGS, these technologies continue to evolve, enhancing genomic studies and contributing to improved understanding and treatment strategies for brain cancer.
• Methods: We compiled common polymorphisms based on citation frequency and population data from the NCBI database, and subsequently analyzed them using the MEGAGENE software. The goal was to identify which polymorphisms most effectively characterize the Iranian population profile and to determine the phenotypes they are likely to express.
• Results: We examined among almost all common polymorphisms three polymorphisms based on the analyses provided by the Megagene software. Using the software's analysis, we investigated these three common SNPs (RS6010620, RS2302427, RS3130) along with their citations and population data (RS2302427: Citation: 10 population: 93704), (RS3130: Citation: 9 population: 8510), (RS6010620: (Citation: 48, population: 692).
• Conclusion: We have examined the side effects of common chemotherapy drugs produced or imported in Iran using MEGAGENE software and analyzed the proposed drugs along with their side effects in relation to phenotypes associated with relevant genetic polymorphisms. We found that for the chemotherapy drugs Temozolomide and Carmustine, side effects may have a genetic basis, such as seizures for Temozolomide and inflammation and infection for Carmustine (Carmustine: Genes DKC1, RS2728726, and CCDC26, RS55705857; Temozolomide: Gene RBFOX1, RS8044700). We recommend that before prescribing these drugs, the patient's genetic regions associated with these polymorphisms be examined. This approach can help select a more appropriate drug, potentially reducing side effects and improving treatment outcomes.
• Keywords: brain cancer,Temozolomid Carmustine, RS6010620, RS62302427,